StreetInsider.com News Articles

Braveheart Bio to Participate in Stifel Cardiometabolic Forum

Wed, 16 Sep 2026 16:30:00 -0400

SAN FRANCISCO, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, today announced that it will participate in the Stifel Virtual Cardiometabolic Forum, being held September 30. Management will participate in a fireside chat on Wednesday, September 30, 2026, at 12:30 p.m. EDT.

Interested parties may access a live webcast by visiting the News & Events section of the Braveheart website at https://ir.braveheart.bio/, with a replay available in a temporary archive following the event.

About

Braveheart Bio to Participate in Stifel Cardiometabolic Forum

Wed, 16 Sep 2026 16:30:00 -0400

SAN FRANCISCO, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, today announced that it will participate in the Stifel Virtual Cardiometabolic Forum, being held September 30. Management will participate in a fireside chat on Wednesday, September 30, 2026, at 12:30 p.m. EDT.

Interested parties may access a live webcast by visiting the News & Events section of the Braveheart website at https://ir.braveheart.bio/, with a replay available in a temporary archive following the event.

About

Goldman Sachs Reiterates Buy Rating on Braveheart Bio (BRVE)

Mon, 14 Sep 2026 07:51:36 -0400

Goldman Sachs analyst Salveen Richter reiterated a Buy rating and $48.00 price target on Braveheart Bio (NASDAQ: BRVE)

For an analyst ratings summary and ratings history on Braveheart Bio click here. For more ratings news on Braveheart Bio click here.

Shares of Braveheart Bio closed at $26.64 yesterday.

Stifel Reiterates Buy Rating on Braveheart Bio (BRVE)

Wed, 09 Sep 2026 09:35:14 -0400

Stifel analyst James Condulis reiterated a Buy rating and $45.00 price target on Braveheart Bio (NASDAQ: BRVE).
The analyst commented, "We're reiterating our Buy rating on BRVE following their 2Q26 report as key timelines (LIONHEART-HCM ph3 initiated; NOBLEHEART-HCM ph3 initiating 1H27) remain on-track. Highlighted in our recent initiation (LINK), following a robust ph2 program, we think BHB-1893 is de-risked in both oHCM/nHCM with tangible ways to win even as a later entrant (re:potentially improved titration/convenience--better efficacy/safety is upside in our view). More broadly though we're big believers HCM (we expect CYTK/aficamten to only further validate this market with a continued strong

Braveheart Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

Tue, 08 Sep 2026 16:03:00 -0400

Phase 3 LIONHEART-HCM Trial of BHB-1893 in Obstructive Hypertrophic Cardiomyopathy (oHCM) Initiated

Cash and Cash Equivalents of $122.8 Million as of June 30, 2026, or $527.3 Million After Giving Effect to Braveheart Bio's Initial Public Offering, Expected to Support Advancement of BHB-1893 Through Late-Stage Clinical Development

SAN FRANCISCO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases, today reported unaudited financial results for the second quarter ended June 30, 2026, and provided a business update.

Braveheart Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

Tue, 08 Sep 2026 16:03:00 -0400

Phase 3 LIONHEART-HCM Trial of BHB-1893 in Obstructive Hypertrophic Cardiomyopathy (oHCM) Initiated

Cash and Cash Equivalents of $122.8 Million as of June 30, 2026, or $527.3 Million After Giving Effect to Braveheart Bio's Initial Public Offering, Expected to Support Advancement of BHB-1893 Through Late-Stage Clinical Development

SAN FRANCISCO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases, today reported unaudited financial results for the second quarter ended June 30, 2026, and provided a business update.

Braveheart Bio to Participate in Cantor Global Healthcare Conference

Tue, 01 Sep 2026 16:30:00 -0400

SAN FRANCISCO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, today announced that it will participate in the Cantor Global Healthcare Conference, being held September 9-11 in New York, NY. Management will participate in a fireside chat on Thursday, September 10, 2026 at 3:20 p.m. EDT.

Interested parties may access a live webcast by visiting the News & Events section of the Braveheart website at https://ir.braveheart.bio/, with replays available in a temporary archive following the

Braveheart Bio to Participate in Cantor Global Healthcare Conference

Tue, 01 Sep 2026 16:30:00 -0400

SAN FRANCISCO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, today announced that it will participate in the Cantor Global Healthcare Conference, being held September 9-11 in New York, NY. Management will participate in a fireside chat on Thursday, September 10, 2026 at 3:20 p.m. EDT.

Interested parties may access a live webcast by visiting the News & Events section of the Braveheart website at https://ir.braveheart.bio/, with replays available in a temporary archive following the

Jefferies starts biopharma firm Braveheart at Buy after IPO

Mon, 31 Aug 2026 06:58:32 -0400

Investing.com -- Jefferies initiated coverage of Braveheart Bio with a Buy rating and a $48 price target, implying roughly 75% upside from the stock’s prior closing price. The move comes after the company priced its initial public offering (IPO) at $18 per share earlier this month, raising $382.5 million in one of the largest biotech debuts of 2026.

The clinical-stage biotech is developing BHB-1893, an oral cardiac myosin inhibitor licensed from China-based Hengrui in September 2025, for hypertrophic cardiomyopathy (HCM), a progressive heart disorder affecting more than 700,000 U.S. patients.

Jefferies analysts led by Andrew Tsai said the drug "could offer superior attributes"

Jefferies starts biopharma firm Braveheart at Buy after IPO

Mon, 31 Aug 2026 06:58:32 -0400

Investing.com -- Jefferies initiated coverage of Braveheart Bio with a Buy rating and a $48 price target, implying roughly 75% upside from the stock’s prior closing price. The move comes after the company priced its initial public offering (IPO) at $18 per share earlier this month, raising $382.5 million in one of the largest biotech debuts of 2026.

The clinical-stage biotech is developing BHB-1893, an oral cardiac myosin inhibitor licensed from China-based Hengrui in September 2025, for hypertrophic cardiomyopathy (HCM), a progressive heart disorder affecting more than 700,000 U.S. patients.

Jefferies analysts led by Andrew Tsai said the drug "could offer superior attributes"

Cantor Fitzgerald Starts Braveheart Bio (BRVE) at Overweight

Mon, 31 Aug 2026 06:37:01 -0400
(Updated - August 31, 2026 6:37 AM EDT)
Cantor Fitzgerald analyst Olivia Brayer Saunders initiates coverage on Braveheart Bio (NASDAQ: BRVE) with a Overweight rating and a price target of $40.00.
The analyst comments "We’re initiating coverage of Braveheart Bio (BRVE) with an Overweight rating and $40 price target. The stock has already had a strong debut postIPO. We think there’s still plenty to play for from here. For those newer to the story, BRVE is essentially a one-asset HCM company built around BHB-1893, a next-generation cardiac myosin inhibitor (CMI) licensed from Hengrui after the class had already been clinically validated. The

Cantor Fitzgerald Starts Braveheart Bio (BRVE) at Overweight

Mon, 31 Aug 2026 06:37:01 -0400
(Updated - August 31, 2026 6:37 AM EDT)
Cantor Fitzgerald analyst Olivia Brayer Saunders initiates coverage on Braveheart Bio (NASDAQ: BRVE) with a Overweight rating and a price target of $40.00.
The analyst comments "We’re initiating coverage of Braveheart Bio (BRVE) with an Overweight rating and $40 price target. The stock has already had a strong debut postIPO. We think there’s still plenty to play for from here. For those newer to the story, BRVE is essentially a one-asset HCM company built around BHB-1893, a next-generation cardiac myosin inhibitor (CMI) licensed from Hengrui after the class had already been clinically validated. The

TD Cowen Starts Braveheart Bio (BRVE) at Buy

Mon, 31 Aug 2026 05:29:47 -0400
(Updated - August 31, 2026 5:29 AM EDT)
TD Cowen analyst Tyler Van Buren initiates coverage on Braveheart Bio (NASDAQ: BRVE) with a Buy rating.
THe analyst comments "BHB-1893 has generated one of the most differentiated CMI datasets we have seen, demonstrating rapid and deep LVOT gradient reduction, a lower "LVEF cost," and encouraging remodeling signals in nHCM. With Phase III studies poised to begin in both oHCM and nHCM, we believe BHB-1893 has the potential to emerge as a BIC therapy in HCM, and we initiate at Buy and estimate >$5B of global sales by 2035."
For an analyst ratings summary and

TD Cowen Starts Braveheart Bio (BRVE) at Buy

Mon, 31 Aug 2026 05:29:47 -0400
(Updated - August 31, 2026 5:29 AM EDT)
TD Cowen analyst Tyler Van Buren initiates coverage on Braveheart Bio (NASDAQ: BRVE) with a Buy rating.
THe analyst comments "BHB-1893 has generated one of the most differentiated CMI datasets we have seen, demonstrating rapid and deep LVOT gradient reduction, a lower "LVEF cost," and encouraging remodeling signals in nHCM. With Phase III studies poised to begin in both oHCM and nHCM, we believe BHB-1893 has the potential to emerge as a BIC therapy in HCM, and we initiate at Buy and estimate >$5B of global sales by 2035."
For an analyst ratings summary and

Stifel Starts Braveheart Bio (BRVE) at Buy

Mon, 31 Aug 2026 02:50:49 -0400

Stifel analyst James Condulis initiates coverage on Braveheart Bio (NASDAQ: BRVE) with a Buy rating and a price target of $45.00.
The analyst comments: “We’re initiating coverage of BRVE with a Buy and $45 TP. Bottom line: (1) we’re big believers in the HCM market; (2) we think BHB-1893 is de-risked in both oHCM/nHCM after a robust ph2 program where we’re confident the Chinese data will translate; (3) we think there are tangible ways for BHB-1893 to "win" even as a later entrant re:titration/convenience (better efficacy/safety is upside in our view— maybe more likely in nHCM but just being a potential

Stifel Starts Braveheart Bio (BRVE) at Buy

Mon, 31 Aug 2026 02:50:49 -0400

Stifel analyst James Condulis initiates coverage on Braveheart Bio (NASDAQ: BRVE) with a Buy rating and a price target of $45.00.
The analyst comments: “We’re initiating coverage of BRVE with a Buy and $45 TP. Bottom line: (1) we’re big believers in the HCM market; (2) we think BHB-1893 is de-risked in both oHCM/nHCM after a robust ph2 program where we’re confident the Chinese data will translate; (3) we think there are tangible ways for BHB-1893 to "win" even as a later entrant re:titration/convenience (better efficacy/safety is upside in our view— maybe more likely in nHCM but just being a potential

Jefferies Starts Braveheart Bio (BRVE) at Buy

Mon, 31 Aug 2026 02:49:07 -0400

Jefferies analyst Andrew Tsai initiates coverage on Braveheart Bio (NASDAQ: BRVE) with a Buy rating and a price target of $48.00.
The analyst comments: “Two Phase II datasets from China-partner Hengrui suggest BHB-1893 (oral CMI) could be differentiated in oHCM/nHCM cardiomyopathy ($4-5B+ oppty) in terms of dosing convenience, better safety, and superior efficacy. In 2026-27, many datasets could help establish BHB-1893's pot'l superiority: (1) Phase III oHCM data in H1:27 (China), (2) Long-term Phase II nHCM data in H1:27 (China), (3) Interim Phase III oHCM data in H2:27 (global). Initiate BUY, $48 PT.
In-licensed from Hengrui in Sep 2025, BHB-1893 (oral BID

Jefferies Starts Braveheart Bio (BRVE) at Buy

Mon, 31 Aug 2026 02:49:07 -0400

Jefferies analyst Andrew Tsai initiates coverage on Braveheart Bio (NASDAQ: BRVE) with a Buy rating and a price target of $48.00.
The analyst comments: “Two Phase II datasets from China-partner Hengrui suggest BHB-1893 (oral CMI) could be differentiated in oHCM/nHCM cardiomyopathy ($4-5B+ oppty) in terms of dosing convenience, better safety, and superior efficacy. In 2026-27, many datasets could help establish BHB-1893's pot'l superiority: (1) Phase III oHCM data in H1:27 (China), (2) Long-term Phase II nHCM data in H1:27 (China), (3) Interim Phase III oHCM data in H2:27 (global). Initiate BUY, $48 PT.
In-licensed from Hengrui in Sep 2025, BHB-1893 (oral BID

Goldman Sachs Starts Braveheart Bio (BRVE) at Buy

Mon, 31 Aug 2026 02:04:48 -0400

Goldman Sachs analyst Salveen Richter initiates coverage on Braveheart Bio (NASDAQ: BRVE) with a Buy rating and a price target of $48.00.
The analyst comments: “BRVE is a clinical-stage biotechnology company developing BHB-1893, a next-generation oral cardiac myosin inhibitor (CMI), for obstructive (oHCM) and non-obstructive hypertrophic cardiomyopathy (nHCM). We believe HCM represents a large and underpenetrated cardiovascular market, with >700K prevalent patients in the U.S. and a diagnosed population that continues to expand on greater physician awareness and targeted treatment adoption. While the approvals of BMY's Camzyos and CYTK's Myqorzo have clinically validated cardiac myosin inhibition, our KOL diligence suggests significant

Goldman Sachs Starts Braveheart Bio (BRVE) at Buy

Mon, 31 Aug 2026 02:04:48 -0400

Goldman Sachs analyst Salveen Richter initiates coverage on Braveheart Bio (NASDAQ: BRVE) with a Buy rating and a price target of $48.00.
The analyst comments: “BRVE is a clinical-stage biotechnology company developing BHB-1893, a next-generation oral cardiac myosin inhibitor (CMI), for obstructive (oHCM) and non-obstructive hypertrophic cardiomyopathy (nHCM). We believe HCM represents a large and underpenetrated cardiovascular market, with >700K prevalent patients in the U.S. and a diagnosed population that continues to expand on greater physician awareness and targeted treatment adoption. While the approvals of BMY's Camzyos and CYTK's Myqorzo have clinically validated cardiac myosin inhibition, our KOL diligence suggests significant

Braveheart Bio raises $439.9M in upsized Nasdaq IPO

Fri, 07 Aug 2026 16:05:10 -0400

Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company, closed its initial public offering of 24,437,500 shares of common stock at $18.00 per share, according to a press release statement.

The total share count includes the full exercise by underwriters of an option to purchase 3,187,500 additional shares. All shares were offered by Braveheart Bio. Gross proceeds from the offering totaled $439.9 million before deducting underwriting discounts, commissions, and other offering expenses.

The shares began trading on the Nasdaq Global Market on Aug. 6, 2026, under the ticker symbol "BRVE."

Goldman Sachs & Co. LLC, Jefferies, TD Cowen, Stifel, and Cantor served as

Braveheart Bio raises $439.9M in upsized Nasdaq IPO

Fri, 07 Aug 2026 16:05:10 -0400

Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company, closed its initial public offering of 24,437,500 shares of common stock at $18.00 per share, according to a press release statement.

The total share count includes the full exercise by underwriters of an option to purchase 3,187,500 additional shares. All shares were offered by Braveheart Bio. Gross proceeds from the offering totaled $439.9 million before deducting underwriting discounts, commissions, and other offering expenses.

The shares began trading on the Nasdaq Global Market on Aug. 6, 2026, under the ticker symbol "BRVE."

Goldman Sachs & Co. LLC, Jefferies, TD Cowen, Stifel, and Cantor served as

Braveheart Bio Announces Closing of Upsized Initial Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Fri, 07 Aug 2026 16:05:00 -0400

SAN FRANCISCO, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, today announced the closing of its upsized initial public offering of an aggregate of 24,437,500 shares of its common stock at an initial public offering price of $18.00 per share, including the full exercise by the underwriters of their option to purchase 3,187,500 additional shares. All shares of common stock were offered by Braveheart Bio. The shares began trading on the Nasdaq Global Market on August 6, 2026 under

Braveheart Bio Announces Closing of Upsized Initial Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Fri, 07 Aug 2026 16:05:00 -0400

SAN FRANCISCO, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, today announced the closing of its upsized initial public offering of an aggregate of 24,437,500 shares of its common stock at an initial public offering price of $18.00 per share, including the full exercise by the underwriters of their option to purchase 3,187,500 additional shares. All shares of common stock were offered by Braveheart Bio. The shares began trading on the Nasdaq Global Market on August 6, 2026 under

Braveheart Bio shares surge 68% in New York trading debut

Thu, 06 Aug 2026 13:08:39 -0400

Investing.com -- Braveheart Bio Inc. shares rose 68% in the company's first day of trading on Thursday after the clinical-stage biopharmaceutical firm completed a $382.5 million initial public offering in the United States.
The stock opened at $30.20 per share in New York, climbing above the IPO price of $18. The company's market value reached $2.13 billion based on outstanding shares.
Braveheart Bio, established in 2024, is working on BHB-1893, its primary drug candidate designed to treat hypertrophic cardiomyopathy, an inherited heart condition that impairs the heart's ability to pump blood. The company obtained licensing rights for the asset from Jiangsu Hengrui